RespireRx Pharmaceuticals Inc. OTC:RSPI

RespireRx Pharmaceuticals stock price today

$0.001
-0.00
-42.11%
Financial Health
0
1
2
3
4
5
6
7
8
9

RespireRx Pharmaceuticals stock price monthly change

+53.85%
month

RespireRx Pharmaceuticals stock price quarterly change

+53.85%
quarter

RespireRx Pharmaceuticals stock price yearly change

+122.22%
year

RespireRx Pharmaceuticals key metrics

Market Cap
837.15K
Enterprise value
2.92M
P/E
-0.06
EV/Sales
N/A
EV/EBITDA
-1.36
Price/Sales
N/A
Price/Book
-0.03
PEG ratio
N/A
EPS
-0.01
Revenue
N/A
EBITDA
-1.48M
Income
-1.94M
Revenue Q/Q
N/A
Revenue Y/Y
N/A
Profit margin
0%
Oper. margin
0%
Gross margin
0%
EBIT margin
0%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

RespireRx Pharmaceuticals stock price history

RespireRx Pharmaceuticals stock forecast

RespireRx Pharmaceuticals financial statements

RespireRx Pharmaceuticals Inc. (OTC:RSPI): Profit margin
Dec 2022 0 -317.15K
Mar 2023 0 -537.02K
Jun 2023 0 -681.03K
Sep 2023 0 -409.16K
RespireRx Pharmaceuticals Inc. (OTC:RSPI): Debt to assets
Dec 2022 22781 11.90M 52250.13%
Mar 2023 95887 12.40M 12938.43%
Jun 2023 141276 12.28M 8694.77%
Sep 2023 108664 12.40M 11416.03%
RespireRx Pharmaceuticals Inc. (OTC:RSPI): Cash Flow
Dec 2022 11.15K 0 -11.12K
Mar 2023 -29.18K 0 29.23K
Jun 2023 -128.57K 0 135.76K
Sep 2023 -100.95K 0 100K

RespireRx Pharmaceuticals alternative data

RespireRx Pharmaceuticals Inc. (OTC:RSPI): Employee count
Aug 2023 2
Sep 2023 2
Oct 2023 2
Nov 2023 2
Dec 2023 2
Jan 2024 2
Feb 2024 2
Mar 2024 2
Apr 2024 2
May 2024 2
Jun 2024 2
Jul 2024 2

RespireRx Pharmaceuticals other data

RespireRx Pharmaceuticals Inc. (OTC:RSPI): Insider trades (number of shares)
Period Buy Sel
Sep 2018 47620 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
LIPPA ARNOLD director, officer: Exec. Chairm..
Common Stock 47,620 N/A N/A
Purchase
MANUSO JAMES S J director, officer: President an..
Common Stock 1,097 N/A N/A
Purchase
MANUSO JAMES S J director, officer: President an..
Common Stock Warrants (right to buy) 2,195 N/A N/A
Sale
MARGOLIS JEFF ELIOT director, 10 percent owner, off..
Common Stock 483,872 N/A N/A
Purchase
MANUSO JAMES S J director, officer: President an..
Common Stock 11,887,779 N/A N/A
Purchase
MANUSO JAMES S J director, officer: President an..
Common Stock Warrants (right to buy) 23,775,558 N/A N/A
Purchase
LIPPA ARNOLD director, officer: Exec. Chairm..
Series G 1.5% Convertible Preferred Stock 250 N/A N/A
Purchase
SAMYANG OPTICS CO., LTD 10 percent owner
common stock 6,765,466 N/A N/A
Purchase
SAMYANG OPTICS CO., LTD 10 percent owner
Warrant to Purchase Common Stock 1,691,367 N/A N/A
Sale
SAMYANG OPTICS CO., LTD 10 percent owner
common stock 6,765,466 N/A N/A
Wednesday, 29 May 2024
globenewswire.com
Wednesday, 20 March 2024
globenewswire.com
Tuesday, 13 February 2024
Proactive Investors
Monday, 22 January 2024
Proactive Investors
Thursday, 4 January 2024
Proactive Investors
Monday, 11 December 2023
Proactive Investors
Thursday, 12 October 2023
Proactive Investors
Wednesday, 24 May 2023
Proactive Investors
Monday, 3 April 2023
Proactive Investors
Tuesday, 28 March 2023
Proactive Investors
Wednesday, 1 March 2023
Proactive Investors
Wednesday, 1 February 2023
Proactive Investors
Monday, 23 January 2023
Proactive Investors
Thursday, 12 January 2023
Proactive Investors
Monday, 5 December 2022
Proactive Investors
Thursday, 17 November 2022
Proactive Investors
Monday, 8 August 2022
Proactive Investors
Tuesday, 17 May 2022
Proactive Investors
GlobeNewsWire
Monday, 16 May 2022
Proactive Investors
Wednesday, 23 March 2022
Proactive Investors
Thursday, 17 March 2022
Proactive Investors
  • What's the price of RespireRx Pharmaceuticals stock today?

    One share of RespireRx Pharmaceuticals stock can currently be purchased for approximately $0.

  • When is RespireRx Pharmaceuticals's next earnings date?

    Unfortunately, RespireRx Pharmaceuticals's (RSPI) next earnings date is currently unknown.

  • Does RespireRx Pharmaceuticals pay dividends?

    No, RespireRx Pharmaceuticals does not pay dividends.

  • How much money does RespireRx Pharmaceuticals make?

    RespireRx Pharmaceuticals has a market capitalization of 837.15K.

  • What is RespireRx Pharmaceuticals's stock symbol?

    RespireRx Pharmaceuticals Inc. is traded on the OTC under the ticker symbol "RSPI".

  • What is RespireRx Pharmaceuticals's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of RespireRx Pharmaceuticals?

    Shares of RespireRx Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • How many employees does RespireRx Pharmaceuticals have?

    As Jul 2024, RespireRx Pharmaceuticals employs 2 workers.

  • When RespireRx Pharmaceuticals went public?

    RespireRx Pharmaceuticals Inc. is publicly traded company for more then 36 years since IPO on 18 Jul 1989.

  • What is RespireRx Pharmaceuticals's official website?

    The official website for RespireRx Pharmaceuticals is respirerx.com.

  • Where are RespireRx Pharmaceuticals's headquarters?

    RespireRx Pharmaceuticals is headquartered at 126 Valley Road, Glen Rock, NJ.

  • How can i contact RespireRx Pharmaceuticals?

    RespireRx Pharmaceuticals's mailing address is 126 Valley Road, Glen Rock, NJ and company can be reached via phone at +20 14444947.

RespireRx Pharmaceuticals company profile:

RespireRx Pharmaceuticals Inc.

respirerx.com
Exchange:

OTC

Full time employees:

2

Industry:

Biotechnology

Sector:

Healthcare

RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS and obstructive sleep apnea; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression, as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.

126 Valley Road
Glen Rock, NJ 07452

CIK: 0000849636
ISIN: US7612273059
CUSIP: 761227305